Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Reflecting the health opportunity costs of funding decisions within value frameworks: Initial estimates and the need for further research.

Ochalek J, Lomas J.

Clin Ther. 2020 Jan 16. pii: S0149-2918(19)30585-5. doi: 10.1016/j.clinthera.2019.12.002. [Epub ahead of print]

PMID:
31955967
2.

Squaring the cube: Towards an operational model of optimal universal health coverage.

Ochalek J, Manthalu G, Smith PC.

J Health Econ. 2020 Jan 16:102282. doi: 10.1016/j.jhealeco.2019.102282. [Epub ahead of print]

3.

A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities.

Arnold M, Griffin S, Ochalek J, Revill P, Walker S.

Cost Eff Resour Alloc. 2019 Mar 20;17:7. doi: 10.1186/s12962-019-0175-6. eCollection 2019.

4.

Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data.

Ochalek J, Lomas J, Claxton K.

BMJ Glob Health. 2018 Nov 5;3(6):e000964. doi: 10.1136/bmjgh-2018-000964. eCollection 2018. Erratum in: BMJ Glob Health. 2019 Jun 4;4(3):e000964corr1.

5.

Supporting the development of a health benefits package in Malawi.

Ochalek J, Revill P, Manthalu G, McGuire F, Nkhoma D, Rollinger A, Sculpher M, Claxton K.

BMJ Glob Health. 2018 Apr 9;3(2):e000607. doi: 10.1136/bmjgh-2017-000607. eCollection 2018.

6.

Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Thokala P, Ochalek J, Leech AA, Tong T.

Pharmacoeconomics. 2018 May;36(5):509-522. doi: 10.1007/s40273-017-0606-1. Review.

7.

Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.

Tierrablanca LE, Ochalek J, Ford D, Babiker A, Gibb D, Butler K, Turkova A, Griffin S, Revill P; BREATHER (PENTA 16) Trial Group.

Medicine (Baltimore). 2018 Feb;97(5):e9698. doi: 10.1097/MD.0000000000009698. Erratum in: Medicine (Baltimore). 2018 Feb;97(7):e0012.

8.

Causal effects of HIV on employment status in low-income settings.

Ochalek J, Revill P, van den Berg B.

Econ Hum Biol. 2017 Nov;27(Pt A):248-260. doi: 10.1016/j.ehb.2017.09.001. Epub 2017 Sep 8.

9.

Novel styryl-indoles as small molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): Synthesis and biological evaluation.

Ferla S, Gomaa MS, Brancale A, Zhu J, Ochalek JT, DeLuca HF, Simons C.

Eur J Med Chem. 2014 Nov 24;87:39-51. doi: 10.1016/j.ejmech.2014.09.035. Epub 2014 Sep 16.

PMID:
25240094
10.

Synthesis and Biological Activity of 25-Hydroxy-2-methylene-vitamin D3 analogues monohydroxylated in the A-ring.

Sibilska IK, Sicinski RR, Ochalek JT, Plum LA, DeLuca HF.

J Med Chem. 2014 Oct 23;57(20):8319-31. doi: 10.1021/jm500750b. Epub 2014 Oct 2.

PMID:
25221942
11.

Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation.

Ferla S, Aboraia AS, Brancale A, Pepper CJ, Zhu J, Ochalek JT, DeLuca HF, Simons C.

J Med Chem. 2014 Sep 25;57(18):7702-15. doi: 10.1021/jm5009314. Epub 2014 Sep 8.

PMID:
25148392
12.

CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo.

Zhu JG, Ochalek JT, Kaufmann M, Jones G, Deluca HF.

Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15650-5. doi: 10.1073/pnas.1315006110. Epub 2013 Sep 9.

Supplemental Content

Loading ...
Support Center